Biosensors has earned a CE mark certification for its BioFreedom Ultra drug-coated coronary stent system.

The new, thin-strut stent is designed to optimize coronary procedures for patients at high risk of bleeding. The 84-micrometer device delivers the company’s proprietary drug, Biolimus A9, that promotes rapid growth of vascular tissue for one month.

Biosensors said it also is developing a Biolimus A9-eluting device for the treatment of patients with coronary artery disease.